Coronavirus disease (COVID-19) is an infectious disease caused by the coronavirus SARS-CoV-2. Here we have collected APR news related to the COVID-19 pandemic, vaccination efforts and emerging treatments.
Wednesday, March 23, 2022
Thermo Fisher Scientific Inc., announced its collaboration with the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) Initiative, Helix, and Rosalind aimed at developing a ...
read more
The FDA is announcing a virtual meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Wed., April 6, to discuss considerations for future COVID-19 vaccine booster ...
read more
Health Canada authorized the use of the Moderna Spikevax (50 mcg) COVID-19 vaccine in children 6 to 11 years of age. This is the second COVID-19 vaccine authorized in Canada for use in this younger ...
read more
The Medicines Patent Pool (MPP) announced that it has signed agreements with 35 companies to manufacture the generic version of Pfizer's oral COVID-19 treatment nirmatrelvir, which in combination with...
read more
Pfizer Inc. and BioNTech SE announced the companies have submitted an application to the FDA for Emergency Use Authorization (EUA) of an additional booster dose adults 65 years of age and older who ...
read more
Akston Biosciences Corporation and Biolexis, a division of Stelis Biopharma Limited have entered into a licensing, manufacturing and commercialization agreement for Akston’s AKS-452, a protein subunit...
read more
AbbVie and Scripps Research announced a global collaboration to develop potential novel, direct-acting antiviral treatments for COVID-19.
read more
Elektrofi & IPA announced they are entering into a collaboration to explore a high-concentration formulation of IPA’s COVID-19 antibody cocktail, PolyTope® TATX-03. This collaboration aims to generate...
read more
Wednesday, March 09, 2022
Johnson & Johnson announced the completion of a landmark agreement between Janssen Pharmaceuticals, Inc., and manufacturer Aspen SA Operations (Pty) Ltd, based in South Africa, to enable the first ...
read more
Wednesday, March 02, 2022
SAB Biotherapeutics reported that due to low hospitalization and death rates in the trial, the National Institutes of Health’s (NIH) ACTIV-2 Program is discontinuing enrollment in its Phase 3 COVID-19...
read more
Monday, February 28, 2022
Vaccines have revolutionized the world’s ability to prevent, mitigate the impact of and, in some cases, eliminate the threat of certain infectious diseases and improve overall health. The clinical ...
read more
Monday, February 28, 2022
All hand sanitizers, whether used by consumers or healthcare professionals, are considered over-the-counter (OTC) drugs that are regulated by the FDA. The most common type of hand sanitizer has ...
read more
Monday, February 28, 2022
Seqirus announced the renewal of a five-year agreement with the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and...
read more
Friday, February 25, 2022
The FDA has revised the emergency use authorization for Evusheld (tixagevimab co-packaged with cilgavimab) to change the initial dose for the authorized use as pre-exposure prophylaxis (prevention) of...
read more
Friday, February 25, 2022
Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) announced that Health Canada has granted approval for COVIFENZ®, COVID-19 vaccine, (plant-based virus-like...
read more